The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results Sallman, D., Asch, A., Kambhampati, S., Al Malki, M., Zeidner, J., Donnellan, W., Lee, D., Vyas, P., Jeyakumar, D., Mannis, G., Tanaka, T., Chai-Ho, W., Larson, R., Whiteley, A., Marcucci, G., Komrokji, R., Garcia-Manero, G., Van Elk, J., Lin, M., Maute, R., Volkmer, J., Takimoto, C., Chao, M., Daver, N. CIG MEDIA GROUP, LP. 2021: S290

View details for Web of Science ID 000691910500133